The Predictive Value of Myoglobin for COVID-19-Related Adverse Outcomes: A Systematic Review and Meta-Analysis.
The Predictive Value of Myoglobin for COVID-19-Related Adverse Outcomes: A Systematic Review and Meta-Analysis.
复制标题
肌红蛋白对 COVID-19 相关不良后果的预测价值：系统评价和荟萃分析
DOI：
10.3389/fcvm.2021.757799
复制
发表时间：
2021
影响因子：
3.6
通讯作者：
Li P
中科院分区：
文献类型：
--
作者：
Ma C;Tu D;Gu J;Xu Q;Hou P;Wu H;Guo Z;Bai Y;Zhao X;Li P
目的：在许多2019冠状病毒病（COVID-19）患者中检测到心脏损伤，并已被证明与不良结局密切相关。然而，尚未确定用于预测COVID-19预后的最佳心脏生物标志物。方法：检索PubMed、Web of Science和Embase数据库中2019年12月1日至2021年9月8日期间发表的文章。纳入了检查COVID-19患者不同心脏生物标志物异常的合格研究。提取患病率和比值比（OR）。通过荟萃分析获得汇总估计值和相应的95%置信区间（95% CI）。结果：本次荟萃分析共纳入63项研究，64，319例COVID-19患者。在COVID-19普通人群中，心肌肌钙蛋白I（cTnI）和肌红蛋白（Mb）升高的患病率分别为22.9%（19-27%）和13.5%（10.6-16.4%）。然而，在重度COVID-19患者中，Mb升高比cTnI升高更常见[37.7（23.3-52.1%）vs.30.7%（24.7-37.1%）]。此外，与cTnI相比，Mb升高与严重度（Mb，r = 13.9 vs. cTnI，r = 3.93）和病死率（Mb，r = 15.42 vs. cTnI，r = 3.04）也有更高的相关性。值得注意的是，与cTnI相比，Mb水平升高也与更高的重度疾病[Mb，OR = 13.75（10.2-18.54）vs. cTnI，OR = 7.06（3.94-12.65）]和死亡率[Mb，OR = 13.49（9.3-19.58）vs. cTnI，OR = 7.75（4.4-13.66）]相关。结论：患有COVID-19和Mb水平升高的患者发生严重疾病和死亡的风险显著较高。Mb的升高可以作为预测COVID-19相关不良结果的标志。Prospero注册号：https://www.crd.york.ac.uk/prospero/display_record.php? ID=CRD42020175133，CRD42020175133。
Objective: Cardiac injury is detected in numerous patients with coronavirus disease 2019 (COVID-19) and has been demonstrated to be closely related to poor outcomes. However, an optimal cardiac biomarker for predicting COVID-19 prognosis has not been identified. Methods: The PubMed, Web of Science, and Embase databases were searched for published articles between December 1, 2019 and September 8, 2021. Eligible studies that examined the anomalies of different cardiac biomarkers in patients with COVID-19 were included. The prevalence and odds ratios (ORs) were extracted. Summary estimates and the corresponding 95% confidence intervals (95% CIs) were obtained through meta-analyses. Results: A total of 63 studies, with 64,319 patients with COVID-19, were enrolled in this meta-analysis. The prevalence of elevated cardiac troponin I (cTnI) and myoglobin (Mb) in the general population with COVID-19 was 22.9 (19–27%) and 13.5% (10.6–16.4%), respectively. However, the presence of elevated Mb was more common than elevated cTnI in patients with severe COVID-19 [37.7 (23.3–52.1%) vs.30.7% (24.7–37.1%)]. Moreover, compared with cTnI, the elevation of Mb also demonstrated tendency of higher correlation with case-severity rate (Mb, r = 13.9 vs. cTnI, r = 3.93) and case-fatality rate (Mb, r = 15.42 vs. cTnI, r = 3.04). Notably, elevated Mb level was also associated with higher odds of severe illness [Mb, OR = 13.75 (10.2–18.54) vs. cTnI, OR = 7.06 (3.94–12.65)] and mortality [Mb, OR = 13.49 (9.3–19.58) vs. cTnI, OR = 7.75 (4.4–13.66)] than cTnI. Conclusions: Patients with COVID-19 and elevated Mb levels are at significantly higher risk of severe disease and mortality. Elevation of Mb may serve as a marker for predicting COVID-19-related adverse outcomes. Prospero Registration Number: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020175133, CRD42020175133.
登录
查看更多内容
影响因子：
158.5
作者：
Li, Qun;Guan, Xuhua;Feng, Zijian
通讯作者：
Feng, Zijian
DOI：
10.15557/pimr.2020.0003
发表时间：
2020-01-01
影响因子：
3.6
作者：
通讯作者：
--
影响因子：
5.7
作者：
Collinson, PO;Stubbs, PJ;Kessler, AC
通讯作者：
Kessler, AC
DOI：
10.1136/bmj.n1943
发表时间：
2021-08-20
期刊：
BMJ (Clinical research ed.)
影响因子：
--
作者：
Chung H;He S;Nasreen S;Sundaram ME;Buchan SA;Wilson SE;Chen B;Calzavara A;Fell DB;Austin PC;Wilson K;Schwartz KL;Brown KA;Gubbay JB;Basta NE;Mahmud SM;Righolt CH;Svenson LW;MacDonald SE;Janjua NZ;Tadrous M;Kwong JC;Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Investigators
通讯作者：
Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Investigators
影响因子：
24
作者：
Kawakami R;Sakamoto A;Kawai K;Gianatti A;Pellegrini D;Nasr A;Kutys B;Guo L;Cornelissen A;Mori M;Sato Y;Pescetelli I;Brivio M;Romero M;Guagliumi G;Virmani R;Finn AV
通讯作者：
Finn AV